# EDGAR Filing Document

**Accession Number:** 0001826470
**File Stem:** 0001193125-25-297206
**Filing Date:** 2025-11
**Character Count:** 33325
**Document Hash:** d46f9e6e3bde17211c3d13892febcd26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-297206.hdr.sgml**: 20251125

**ACCESSION NUMBER**: 0001193125-25-297206

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20251125

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251125

**DATE AS OF CHANGE**: 20251125

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Petco Health & Wellness Company, Inc.
- **CENTRAL INDEX KEY:** 0001826470
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-RETAIL STORES, NEC [5990]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 811005932
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0131

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39878
- **FILM NUMBER:** 251521184

**BUSINESS ADDRESS:**
- **STREET 1:** 10850 VIA FRONTERA
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127
- **BUSINESS PHONE:** 1-858-453-7845

**MAIL ADDRESS:**
- **STREET 1:** 10850 VIA FRONTERA
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PET Acquisition LLC
- **DATE OF NAME CHANGE:** 20200929

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petco Acquisition LLC
- **DATE OF NAME CHANGE:** 20200929

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 25, 2025<br>

------

Petco Health and Wellness Company, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39878 | 81-1005932 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 10850 Via Frontera |  |  |
| San Diego**,** California |  | 92127 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (858) 453-7845<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange on which registered** |
| Class A common stock, par value $0.001 per share | WOOF | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 2.02 Results of Operations and Financial Condition.
On November 25, 2025, Petco Health and Wellness Company, Inc. (the "Company") issued a press release disclosing its financial results for the quarter ended November 1, 2025. The full text of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

## Item 7.01 Regulation FD Disclosure.
The Company has scheduled a webcast call at 4:30 p.m. Eastern Time on November 25, 2025 to discuss the Company's financial results for the quarter ended November 1, 2025. In addition to the press release, an earnings presentation will be made available on the Company's investor relations page at ir.petco.com. A replay of the webcast call will also be made available on the Company's investor relations page approximately two hours after the webcast call.

The information being furnished pursuant to Item 2.02, including Exhibit 99.1, and Item 7.01 of this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liability of that section, and shall not be incorporated by reference into any other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 99.1 | [<u>Press Release, dated November 25, 2025</u>](woof-ex99_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **Petco Health and Wellness Company, Inc.** |
| Date: | November 25, 2025 | By:  | /s/ Giovanni Insana |
|  |  | Name:<br>Title: | Giovanni Insana<br>Chief Legal Officer and Secretary |

---

------

## Exhibit 99.1

Exhibit 99.1

**Petco Reports Third Quarter 2025**

**Financial Results**

***Upwardly Revises Fiscal 2025 Earnings Outlook\****

**San Diego, November 25, 2025** – Petco (Nasdaq: WOOF) today announced its third quarter 2025 financial results.

**Q3 2025 Overview**

• Net sales of $1.5 billion decreased 3.1% year over year in line with the company's third quarter outlook

• Comparable sales decreased 2.2% year over year

• Gross profit margin expanded approximately 75 basis points to 38.9% as a percentage of net sales

• Operating income improved $25.2 million to $29.2 million

• GAAP net income improved $26.0 million to $9.3 million

• Adjusted EBITDA<sup>1</sup> increased $17.3 million to $98.6 million

# "Once again, we delivered on Petco's profitability goals as we continue to execute on our multi-phased transformation," said Joel Anderson, Petco's Chief Executive Officer.

# "Rebuilding the base of our economic model has been a priority in 2025. This strengthened base sets the foundation for a return to growth during fiscal 2026."

# Full Year 2025 Outlook
The company tightened its full year net sales outlook and upwardly revised its full year 2025 earnings guidance increasing the midpoint of its expected adjusted EBITDA range by $6 million. In addition, the company provided its outlook for the fourth quarter of 2025.

---

| | |
|:---|:---|
|  | **FY 2025 Outlook\*** |
| Net Sales | Down 2.5% - 2.8% |
| Adjusted EBITDA | $395 million to $397 million |
| Net interest expense | ~$125 million |
| Capital Expenditures | $125 million - $130 million |
| Depreciation & Amortization | ~$200 million |
| Net Store Closures | ~20 |

---

------

**Fourth Quarter 2025 Outlook**

---

| | |
|:---|:---|
|  | **Q4 2025 Outlook\*** |
| &nbsp;&nbsp;&nbsp;&nbsp;Net Sales | Down low single digits year over year |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA | $93 million to $95 million |

---

\*Assumptions in the outlook include that economic conditions, currency rates and the tax and regulatory landscape remain generally consistent, and that current or planned tariffs on imports into the U.S. from other countries remain at November 25, 2025 levels. Adjusted EBITDA is a non-GAAP financial measure and has not been reconciled to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management's control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide outlook for the comparable GAAP measures. Forward-looking estimates of Adjusted EBITDA are made in a manner consistent with the relevant definitions and assumptions noted herein and in our filings with the Securities and Exchange Commission.

(1)Adjusted EBITDA is a non-GAAP financial measure. See "Non-GAAP Financial Measures" for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

# Earnings Conference Call Webcast Information:

# Management will host an earnings conference call on November 25, 2025 at approximately 4:30 PM Eastern Time to discuss the company's financial results. A live webcast of the conference call will be available on the company's Investor Relations page at https://ir.petco.com/news-and-events/events-and-presentations. A replay of the webcast will be available through the same link approximately two hours after the conference call.

# About Petco:

# We're proud to be "where the pets go" to find everything they need to live their best lives for more than 60 years — from their favorite meals and toys, to trusted supplies and expert support from people who get it, because we live it. We believe in the universal truths of pet parenthood — the boundless boops, missing slippers, late night zoomies and everything in between. And we're here for it. Every tail wag, every vet visit, every step of the way. We nurture the pet-human bond in the aisles of more than 1,500 Petco stores across the U.S., Mexico and Puerto Rico. Customers experience our exclusive selection of pet care products, services, expertise and membership offerings in stores and online at petco.com, and on the Petco app. In 1999, we founded Petco Love. Together, we support thousands of local animal welfare groups nationwide, and have helped find homes for over 7 million animals through in-store adoption events.
**<u>Forward-Looking Statements:</u>**

This earnings release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning expectations, beliefs, plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are not statements of historical fact, including, but not limited to, statements regarding our Q4 and full year 2025 outlook, operational reset of our business, our competitive positioning, profitability, cost action plans and associated cost-savings, our path to sustainable, profitable growth and our expectations regarding tariffs and associated impacts. Such forward-looking statements can generally be identified by the use of forward-looking terms such as "believes," "expects," "may," "intends," "will,"

------

"shall," "should," "anticipates," "opportunity," "illustrative," or the negative thereof or other variations thereon or comparable terminology. Although Petco believes that the expectations and assumptions reflected in these statements are reasonable, there can be no assurance that these expectations will prove to be correct or that any forward-looking results will occur or be realized. Nothing contained in this earnings release is, or should be relied upon as, a promise or representation or warranty as to any future matter, including any matter in respect of the operations or business or financial condition of Petco. All forward-looking statements are based on current expectations and assumptions about future events that may or may not be correct or necessarily take place and that are by their nature subject to significant uncertainties and contingencies, many of which are outside the control of Petco. Forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results or events to differ materially from the potential results or events discussed in the forward-looking statements, including, without limitation, those identified in this earnings release as well as the following: (i) increased competition (including from multi-channel retailers, mass and grocery retailers, and e-Commerce providers); (ii) reduced consumer demand for our products and/or services; (iii) our reliance on key vendors; (iv) our ability to attract and retain qualified employees; (v) risks arising from statutory, regulatory and/or legal developments; (vi) macroeconomic pressures in the markets in which we operate, including inflation, prevailing interest rates and the impact of tariffs; (vii) failure to effectively manage our costs; (viii) our reliance on our information technology systems; (ix) our ability to prevent or effectively respond to a data privacy or security breach; (x) our ability to effectively manage or integrate strategic ventures, alliances or acquisitions and realize the anticipated benefits of such transactions; (xi) economic or regulatory developments that might affect our ability to provide attractive promotional financing; (xii) business interruptions and other supply chain issues; (xiii) catastrophic events, political tensions, conflicts and wars (such as the ongoing conflicts in Ukraine and the Middle East), health crises, and pandemics; (xiv) our ability to maintain positive brand perception and recognition; (xv) product safety and quality concerns; (xvi) changes to labor or employment laws or regulations; (xvii) our ability to effectively manage our real estate portfolio; (xviii) constraints in the capital markets or our vendor credit terms; (xix) changes in our credit ratings; (xx) impairments of the carrying value of our goodwill and other intangible assets; (xxi) our ability to successfully implement our operational adjustments, achieve the expected benefits of our cost action plans and drive improved profitability; (xxii) our ability to deliver sustainable, profitable growth and (xxiii) the other risks, uncertainties and other factors identified under "Risk Factors" and elsewhere in Petco's Securities and Exchange Commission filings. The occurrence of any such factors could significantly alter the results set forth in these statements.

Petco cautions that the foregoing list of risks, uncertainties and other factors is not complete, and forward-looking statements speak only as of the date they are made. Petco undertakes no duty to update publicly any such forward-looking statement, whether as a result of new information, future events or otherwise, except as may be required by applicable law, regulation or other competent legal authority.

---

| | |
|:---|:---|
| Investor Contact | Media Contact |
| Tina Romani | Lisa Stark |
| InvestorRelations@petco.com | pressinquiries@petco.com |

---

------

**PETCO HEALTH AND WELLNESS COMPANY, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(In thousands, except per share amounts)

(Unaudited and subject to reclassification)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **13 Weeks Ended** | **13 Weeks Ended** | **39 Weeks Ended** | **39 Weeks Ended** |
|  | **November 1,<br>2025** | **November 2,<br>2024** | **November 1,<br>2025** | **November 2,<br>2024** |
| Net sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Products | $1209601 | $1263194 | $3677097 | $3806674 |
| &nbsp;&nbsp;&nbsp;&nbsp;Services and other | 254810 | 248243 | 769242 | 757658 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total net sales** | **1464411** | **1511437** | **4446339** | **4564332** |
| Cost of sales: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Products | 739893 | 782240 | 2253321 | 2362065 |
| &nbsp;&nbsp;&nbsp;&nbsp;Services and other | 155503 | 153440 | 468716 | 467125 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of sales | 895396 | 935680 | 2722037 | 2829190 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Gross profit** | **569015** | **575757** | **1724302** | **1735142** |
| Selling, general and administrative expenses | 539819 | 571780 | 1635725 | 1745479 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Operating income (loss)** | **29196** | **3977** | **88577** | **(10337)** |
| Interest income | (1814) | (1346) | (4082) | (2436) |
| Interest expense | 32827 | 35797 | 99618 | 109420 |
| Other non-operating income |  | (8465) |  | (5800) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Loss before income taxes and income from<br> equity method investees** | **(1817)** | **(22009)** | **(6959)** | **(111521)** |
| Income tax benefit | (6276) | (857) | (5035) | (9985) |
| Income from equity method investees | (4871) | (4479) | (13565) | (13557) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net income (loss) attributable to Class A and B-1<br> common stockholders** | $**9330** | $**(16673)** | $**11641** | $**(87979)** |
| **Net income (loss) per Class A and B-1 common share:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.03 | $(0.06) | $0.04 | $(0.32) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.03 | $(0.06) | $0.04 | $(0.32) |
| **Weighted average shares used in computing net income<br> (loss) per Class A and B-1 common share:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 280380 | 274495 | 278995 | 272446 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 288221 | 274495 | 285640 | 272446 |

---

------

**PETCO HEALTH AND WELLNESS COMPANY, INC.**

**CONSOLIDATED BALANCE SHEETS**

(In thousands, except per share amounts)

(Unaudited and subject to reclassification)

---

| | | |
|:---|:---|:---|
|  | **November 1,<br>2025** | **February 1,<br>2025** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $237413 | $165756 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, less allowance for credit losses<sup>1</sup> | 42900 | 40425 |
| &nbsp;&nbsp;&nbsp;&nbsp;Merchandise inventories, net | 617896 | 653329 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 43721 | 53515 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 65470 | 60594 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 1007400 | 973619 |
| Fixed assets | 2342513 | 2265915 |
| Less accumulated depreciation | (1672868) | (1540477) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fixed assets, net | 669645 | 725438 |
| Operating lease right-of-use assets | 1306554 | 1302346 |
| Goodwill | 980064 | 980064 |
| Trade name | 1025000 | 1025000 |
| Other long-term assets | 216461 | 187963 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $5205124 | $5194430 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and book overdrafts | $429978 | $492878 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued salaries and employee benefits | 111919 | 157460 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 209811 | 177079 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 346650 | 306400 |
| &nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt and other lease liabilities | 5102 | 5346 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 1103460 | 1139163 |
| Senior secured credit facilities, net, excluding current portion | 1581950 | 1578091 |
| Operating lease liabilities, excluding current portion | 1035774 | 1037206 |
| Deferred taxes, net | 220651 | 217712 |
| Other long-term liabilities | 105693 | 108628 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 4047528 | 4080800 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Class A common stock<sup>2</sup> | 243 | 239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class B-1 common stock<sup>3</sup> | 38 | 38 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class B-2 common stock<sup>4</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock<sup>5</sup> |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in-capital | 2304491 | 2280495 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (1137418) | (1149059) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (9758) | (18083) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 1157596 | 1113630 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $5205124 | $5194430 |

---

<sup>1.</sup>Allowances for credit losses are $940 and $1,594, respectively

<sup>2.</sup>Class A common stock, $0.001 par value: Authorized - 1.0 billion shares; Issued and outstanding - 243.1 million and 239.1 million shares, respectively

<sup>3.</sup>Class B-1 common stock, $0.001 par value: Authorized - 75.0 million shares; Issued and outstanding - 37.8 million shares

<sup>4.</sup>Class B-2 common stock, $0.000001 par value: Authorized - 75.0 million shares; Issued and outstanding - 37.8 million shares

<sup>5.</sup>Preferred stock, $0.001 par value: Authorized - 25.0 million shares; Issued and outstanding - none

------

**PETCO HEALTH AND WELLNESS COMPANY, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(In thousands)

(Unaudited and subject to reclassification)

---

| | | |
|:---|:---|:---|
|  | **39 Weeks Ended** | **39 Weeks Ended** |
|  | **November 1,<br>2025** | **November 2,<br>2024** |
| **Cash flows from operating activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $11641 | $(87979) |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by <br> operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 148466 | 149414 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt discounts and issuance costs | 3760 | 3661 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for deferred taxes | (50) | (35629) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 25372 | 40705 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairments, write-offs and losses on sale of fixed and other assets | 677 | 8449 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investees | (13565) | (13557) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified out of accumulated other comprehensive loss | (561) | (3035) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash operating lease costs | 308297 | 311347 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-operating loss |  | (5800) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | (2709) | 4287 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Merchandise inventories | 35433 | (6194) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (2437) | 1601 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and book overdrafts | (63121) | (36427) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued salaries and employee benefits | (46238) | 28986 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | 30028 | (817) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (273942) | (280101) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | (523) | 2769 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 160528 | 81680 |
| **Cash flows from investing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for fixed assets | (89960) | (91041) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for acquisitions, net of cash acquired |  | (464) |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for investment |  | (457) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from investment |  | 998 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of assets | 2541 | 1252 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash received from partial surrender of officers' life insurance |  | 206 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (87419) | (89506) |
| **Cash flows from financing activities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Borrowings under long-term debt agreements |  | 201000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Repayments of long-term debt |  | (201000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt refinancing costs |  | (3028) |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments for finance lease liabilities | (4433) | (4608) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from employee stock purchase plan and stock option exercises | 2738 | 2585 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax withholdings on stock-based awards | (3656) | (5251) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock |  | 2500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (5351) | (7802) |
| Net decrease in cash, cash equivalents and restricted cash | 67758 | (15628) |
| Cash, cash equivalents and restricted cash at beginning of period | 181665 | 136649 |
| Cash, cash equivalents and restricted cash at end of period | $249423 | $121021 |

---

------

**<u>NON-GAAP FINANCIAL MEASURES</u>**

The following information provides definitions and reconciliations of the non-GAAP financial measures presented in this earnings release to the most directly comparable financial measures calculated and presented in accordance with generally accepted accounting principles (GAAP). The company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measures in this earnings release may differ from similarly titled measures used by other companies.

**Adjusted EBITDA** 

Adjusted EBITDA is considered a non-GAAP financial measure under the Securities and Exchange Commission's (SEC) rules because it excludes certain amounts included in net income calculated in accordance with GAAP. Management believes that Adjusted EBITDA is a meaningful measure to share with investors because it facilitates comparison of the current period performance with that of the comparable prior period. In addition, Adjusted EBITDA affords investors a view of what management considers to be Petco's core operating performance as well as the ability to make a more informed assessment of such operating performance as compared with that of the prior period. Please see the company's Annual Report on Form 10-K for the fiscal year ended February 1, 2025 filed with the SEC on March 31, 2025 for additional information on Adjusted EBITDA.

The table below reflects the calculation of Adjusted EBITDA for the thirteen and thirty-nine weeks ended November 1, 2025 compared to the thirteen and thirty-nine weeks ended November 2, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **(dollars in thousands)** | **13 Weeks Ended** | **13 Weeks Ended** | **39 Weeks Ended** | **39 Weeks Ended** |
| **Reconciliation of Net Income (Loss) Attributable to Class A<br> and B-1 Common Stockholders to Adjusted EBITDA** | **November 1,<br>2025** | **November 2,<br>2024** | **November 1,<br>2025** | **November 2,<br>2024** |
| **Net income (loss) attributable to Class A and B-1 common<br> stockholders** | $**9330** | $**(16673)** | $**11641** | $**(87979)** |
| Add (deduct): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 31013 | 34451 | 95536 | 106984 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax benefit | (6276) | (857) | (5035) | (9985) |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 49817 | 50109 | 148466 | 149414 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income from equity method investees | (4871) | (4479) | (13565) | (13557) |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset impairments and write offs | 155 | 1380 | 677 | 8449 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity-based compensation | 7163 | 11357 | 25372 | 40705 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-operating income |  | (8465) |  | (5800) |
| &nbsp;&nbsp;&nbsp;&nbsp;Mexico joint venture EBITDA <sup>(1)</sup> | 11662 | 9984 | 32220 | 30382 |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquisition and divestiture-related costs <sup>(2)</sup> |  |  |  | 3719 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other costs <sup>(3)</sup> | 571 | 4429 | 6561 | 18071 |
| **Adjusted EBITDA** | $**98564** | $**81236** | $**301873** | $**240403** |
| Net sales | $1464411 | $1511437 | $4446339 | $4564332 |
| Net margin <sup>(4)</sup> | 0.6% | (1.1%) | 0.3% | (1.9%) |
| Adjusted EBITDA Margin | 6.7% | 5.4% | 6.8% | 5.3% |

---

(1)Mexico joint venture EBITDA represents 50 percent of the entity's operating results for all periods, as adjusted to reflect the results on a basis comparable to Adjusted EBITDA. In the financial statements, this joint venture is accounted for as an equity method investment and reported net of depreciation and income taxes because such a presentation would not reflect the adjustments made in the calculation of Adjusted EBITDA, we include the 50 percent interest in the company's Mexico joint venture on an Adjusted EBITDA basis to ensure consistency. The table below presents a reconciliation of Mexico joint venture net income to Mexico joint venture EBITDA.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **13 Weeks Ended** | **13 Weeks Ended** | **39 Weeks Ended** | **39 Weeks Ended** |
| **(in thousands)** | **November 1,<br>2025** | **November 2,<br>2024** | **November 1,<br>2025** | **November 2,<br>2024** |
| Net income | $9742 | $8958 | $27129 | $27335 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 7725 | 6880 | 21115 | 20824 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax expense | 4498 | 3637 | 12599 | 10996 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign currency loss (gain) | 593 | (106) | 997 | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense, net | 766 | 599 | 2599 | 1615 |
| EBITDA | $23324 | $19968 | $64439 | $60763 |
| **50% of EBITDA** | $**11662** | $**9984** | $**32220** | $**30382** |

---

(2)Acquisition and divestiture-related integration costs include direct costs resulting from acquiring, integrating, or divesting businesses. These include third-party professional and legal fees, losses on sales of divestitures, and other integration-related costs that would not have otherwise been incurred as part of the company's operations.

(3)Other costs include, as incurred: restructuring costs and restructuring-related severance costs; legal reserves associated with significant, non-ordinary course legal or regulatory matters; and costs related to certain significant strategic transactions.

(4)We define net margin as net loss attributable to Class A and B-1 common stockholders divided by net sales and Adjusted EBITDA margin as Adjusted EBITDA divided by net sales.

**Free Cash Flow**

Free Cash Flow is a non-GAAP financial measure that is calculated as net cash provided by operating activities less cash paid for fixed assets. Management believes that Free Cash Flow, which measures the ability to generate additional cash from business operations, is an important financial measure for use in evaluating the company's financial performance.

The table below reflects the calculation of Free Cash Flow for the thirteen and thirty-nine weeks ended November 1, 2025 compared to the thirteen and thirty-nine weeks ended November 2, 2024.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **13 Weeks Ended** | **13 Weeks Ended** | **39 Weeks Ended** | **39 Weeks Ended** |
| **(in thousands)** | **November 1,<br>2025** | **November 2,<br>2024** | **November 1,<br>2025** | **November 2,<br>2024** |
| Net cash provided by operating activities | $90090 | $20724 | $160528 | $81680 |
| Cash paid for fixed assets | (29444) | (31012) | (89960) | (91041) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Free Cash Flow** | $**60646** | $**(10288)** | $**70568** | $**(9361)** |

---

------